The physiological, cellular, and/or genetic basis of a disease is studied to identify potential therapeutic targets. 



Once a potential target has been identified, researchers will then screen thousands of APIs, excipients and/or formulations for potential candidates that act on this target.


After early testing, however, only a small number of compounds look promising and call for further study. 


We are in the age of cell therapy and gene therapy with bioprocessing being a key element. Being able to affect disease at the molecular level is the key, and nanomedicine is a fundamental technology for ushering in the next wave of genetic and molecularly targeted therapeutics.

The NanoAssemblr® Product Suite and Formulation Solutions

NanoAssemblr Spark


The NanoAssemblr® Spark™ produces microlitre volumes of nanomedicines for discovery research.

NanoAssemblr Benchtop


The NanoAssemblr® Benchtop manufactures 1 – 15 mL of nanomedicine per run for nanomedicine development programs.

Formulation Solution Experts



To rapidly reach the formulation proof of concept stage PNI offers highly qualified scientist with extensive formulation development experience through our Formulation Solutions Team.                                                                                                                                           


At every step, our multidisciplinary experts will partner with you to build affirm scientific foundation for the work ahead.

Get Started

To learn how Precision NanoSystems accelerates nanomedicine development from an idea to clinical applications, contact our Technical Sales Team.

Get in Touch

Resource Center


July 01, 2018

Robust low-volume production of nanoparticles for genetic manipulation of cells

Read More PDF

Application Note

July 01, 2018

Seamless scale up of liposomal verteporfin formulations using the NanoAssemblr® Platform

Read More PDF

Publication - Abstract

April 26, 2018

Small Methods

State‐of‐the‐Art Design and Rapid‐Mixing Production Techniques of Lipid Nanoparticles for Nucleic Acid Delivery

Evers, M. J. W., Kulkarni, J. A., van der Meel, R., Cullis, P. R., Vader, P., & Schiffelers, R. M.

Read More

Publication - Abstract

February 27, 2018

Cell Reports

A Single Administration of CRISPR/Cas9 Lipid Nanoparticles Achieves Robust and Persistent In Vivo Genome Editing

J. Finn, A. Smith, M. Patel, L. Shaw, M. Youniss, J. Heteren, T. Dirstine, C. Ciullo, R. Lescarbeau, J. Seitzer, R. Shah...

Read More

Publication - Abstract

November 01, 2018


Changes in the Synaptic Proteome in Tauopathy and Rescue of Tau-Induced Synapse Loss by C1q Antibodies

Dejanovic, B., Huntley, M. A., De Mazière, A., Meilandt, W. J., Wu, T., Srinivasan, K., . . . Sheng, M.

Read More

Publication - Abstract

October 29, 2018

Nature Communications

Cell specific delivery of modified mRNA expressing therapeutic proteins to leukocytes

Nuphar Veiga, Meir Goldsmith, Yasmin Granot, Daniel Rosenblum, Niels Dammes, Ranit Kedmi, Srinivas Ramishetti & Dan Peer...

Read More
Resource Center